<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-lanreotide.xml</id>
  <title>Recalls Watch: Lanreotide</title>
  <link rel="self" href="https://recalls.watch/feed/substance-lanreotide.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-04-15T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/98575/</id>
    <title>Cipla USA, Inc.: Lanreotide Injection and 1 more</title>
    <link href="https://recalls.watch/recall/fda/98575/"/>
    <updated>2026-04-15T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98247/</id>
    <title>Cipla USA, Inc.: Lanreotide Injection</title>
    <link href="https://recalls.watch/recall/fda/98247/"/>
    <updated>2026-01-21T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Presence of Particulate Matter.</summary>
  </entry>
</feed>
